Construction and characterization of Actinobacillus pleuropneumoniae serovar 7 live attenuated vaccine strain co-expressing ApxIA.
- Author:
Jinlin LIU
1
;
Yan CHEN
;
Linlin HU
;
Weicheng BEI
;
Huanchun CHEN
Author Information
1. State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan 430070, China.
- Publication Type:Journal Article
- MeSH:
Actinobacillus Infections;
prevention & control;
veterinary;
Actinobacillus pleuropneumoniae;
classification;
immunology;
Animals;
Bacterial Proteins;
biosynthesis;
genetics;
Bacterial Vaccines;
biosynthesis;
immunology;
Hemolysin Proteins;
biosynthesis;
genetics;
Pleuropneumonia;
microbiology;
prevention & control;
Swine;
Swine Diseases;
microbiology;
prevention & control;
Vaccines, Attenuated;
biosynthesis;
immunology
- From:
Chinese Journal of Biotechnology
2010;26(3):305-310
- CountryChina
- Language:Chinese
-
Abstract:
Actinobacillus pleuropneumoniae (A. pleuropneumoniae), the causative agent of porcine contagious pleuropneumonia (PCP), is a significant pathogen of the world pig industry, vaccination is potentially an effective tool for the prevention of PCP. The purpose of present study was to enhance the immunogenicity of A. pleuropneumoniae live vaccine strain HB04C- (serovar 7), which was unable to express ApxIA, and to develop effective multivalent vaccines for the respiratory pathogens based on the attenuated A. pleuropneumoniae. We introduced a shuttle vector containing intact apxIA gene into HB04C-, generating HB04C2, an A. pleuropneumoniae serovar 7 live attenuated vaccine strain co-expressing ApxIA. Then we investigated the biological characteristics of HB04C2. We found that the shuttle vector expressing ApxIA was stable in HB04C2, and the growth ability of HB04C2 was not affected by the shuttle vector. We observed that HB04C2 elicited detectable antibodies against ApxIA and ApxIIA when it was administrated intratracheally as a live vaccine in pigs, and all immunized pigs were protected from heterologous virulent A. pleuropneumoniae (serovar 1) challenge. In conclusion, we demonstrated that A. pleuropneumoniae live vaccine could be used as a vector for expression of heterologous antigens.
